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Abstract
Objective: To examine when, where and how fractures occur in postmenopausal women.
Methods: We analyzed data from the Global Longitudinal Study of Osteoporosis in Women (GLOW), including women aged
$55 years from the United States of America, Canada, Australia and seven European countries. Women completed
questionnaires including fracture data at baseline and years 1, 2 and 3.
Results: Among 60,393 postmenopausal women, 4122 incident fractures were reported (86% non-hip, non-vertebral
[NHNV], 8% presumably clinical vertebral and 6% hip). Hip fractures were more likely to occur in spring, with little seasonal
variation for NHNV or spine fractures. Hip fractures occurred equally inside or outside the home, whereas 65% of NHNV
fractures occurred outside and 61% of vertebral fractures occurred inside the home. Falls preceded 68–86% of NHNV and
68–83% of hip fractures among women aged #64 to $85 years, increasing with age. About 45% of vertebral fractures were
associated with falls in all age groups except those $85 years, when only 24% occurred after falling.
Conclusion: In this multi-national cohort, fractures occurred throughout the year, with only hip fracture having a seasonal
variation, with a higher proportion in spring. Hip fractures occurred equally within and outside the home, spine fractures
more often in the home, and NHNV fractures outside the home. Falls were a proximate cause of most hip and NHNV
fractures. Postmenopausal women at risk for fracture need counseling about reducing potentially modifiable fracture risk
factors, particularly falls both inside and outside the home and during all seasons of the year.
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Introduction
Osteoporosis is a disease in which age-related reductions in
bone strength predispose to low-trauma fractures. Worldwide,
several million post-menopausal women experience such fractures
each year, with attendant pain and disability, temporary or
permanent reductions in quality of life, and substantial economic
costs borne personally and by healthcare systems [1,2]. Efforts are
being made to identify those at increased risk of fracture, to
optimize calcium and vitamin D use, encourage physical activity
when possible and prescribe effective anti-osteoporosis treatments
as appropriate. To enhance further our ability to counsel women
about fracture risk as they age, we believed that it would be useful
to examine the proximate causes of low-trauma fractures by
ascertaining when during the year women sustain their fractures,
where the events that lead to a fracture event occur, and how
different fractures typically happen.
We evaluated data obtained from the international Global
Longitudinal Study of Osteoporosis in Women (GLOW) to
characterize the circumstances surrounding incident low-trauma
fractures in a primary care population of postmenopausal women
aged 55 years and older from the United States of America,
Canada, Australia and several countries in northern and southern
Europe. In this paper, we offer a descriptive analysis of when,
where and how vertebral, hip, and non-hip, non-vertebral
(NHNV) fractures occurred during the first 3 years of observation
of the GLOW cohort.
Methods
Ethics Statement
Each study site obtained ethics committee approval to conduct
the study in the specific location.
Study Design
GLOW is a longitudinal database study being conducted in
physician practices at 17 sites in 10 countries (Australia, Belgium,
Canada, France, Germany, Italy, The Netherlands, Spain, United
Kingdom and United States of America). These sites are located in
major population centers. Details of the study design and methods
have previously been described [3]. Study sites were selected to
achieve a broad geographic distribution across several countries in
northern and southern Europe and within the US, as well as to
have participation from both Canada and Australia. All study sites
had lead investigators with expertise in osteoporosis and access to a
clinical research team capable of managing a large cohort of
subjects. These lead investigators identified primary care practices
in their region that were members of local research or
administrative networks and able to supply names and addresses
of their patients electronically. The composition of groups varied
by region and included health-system owned practices, managed
practices, independent practice associations and health mainte-
nance organizations. Networks established for the purpose of
general medical research were used only if they were not
established exclusively for osteoporosis research and did not
consist primarily of physicians whose primary focus was academic.
Primary care physicians were defined as doctors who spent most
of their time providing primary healthcare to patients, and
included internists, family practitioners and general practitioners.
Each practice provided a list of the names and addresses of women
aged 55 years and older who had been attended by their physician
in the past 24 months. Sampling was stratified by age to ensure
that two-thirds were women aged 65 years and older. Patients
were excluded if they were unable to complete the study survey
due to cognitive impairment, language barriers, institutionaliza-
tion or illness.
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Questionnaire Development
Questionnaires were designed to be self-administered and the
baseline instrument covered domains that included: patient
characteristics and fracture risk factors, patients’ perceptions
about fracture risk and osteoporosis, past or current use of
medications (including osteoporosis treatment), diagnosed comor-
bidities, healthcare use and access, physical activity, physical
function and quality of life. Where possible, items from published
validated instruments were used, including the National Health
and Nutrition Examination Survey [4], the EQ-5D [5] and the
SF-36 [6] (physical function and vitality components). Questions
that had not been used previously were tested cognitively in the
context of the complete questionnaire in a sample of women in the
study age group. Questionnaires were translated into five
languages (French, Spanish, German, Italian and Dutch) in
addition to English by the University of Massachusetts-Amherst
Translation Center.
Baseline questionnaires, along with invitations to participate in
the study signed by the local principal investigator, were mailed to
all potential subjects. Non-respondents were followed up with
sequential postcard reminders, second questionnaires and tele-
phone interviews. Questionnaires were mailed at 1, 2 and 3 years
to collect information about incident fractures. Questions were
designed to determine which bone or bones were fractured, if the
fracture occurred inside or outside the home, how the fracture
happened, and during what time of year the fracture event
occurred.
Statistical Analysis
Fracture rates during the first 3 years of follow-up are reported
as raw numbers and percentages. Differences were tested using the
chi-square test or Fisher’s exact test in the case of small cell values;
the Mantel-Haenszel chi-square test was used when comparing
ordered age categories. Data are based upon individual subjects
and not individual fractures, and reflect each woman’s first
incident fracture post baseline. Women with missing fracture data
were counted as not fracturing. We have separated the fractures
into three types: hip, vertebral and NHNV (defined as fracture of
the clavicle, upper arm, wrist, rib, pelvis, ankle, upper leg, lower
leg, shoulder, knee, hand, elbow or foot). If a woman had more
than one fracture type in one year, she was excluded from the
analysis. Vertebral fractures were assumed to be clinical vertebral
fractures predominantly, rather than morphometric vertebral
fractures, as these were reported based upon self-report after a
clinical diagnosis by a physician.
The possible answers concerning how the fracture happened
were: ‘‘caused by a fall’’ (fell on stairs; fell climbing on a chair, stool
or ladder; fell out of bed or off a chair; slipped or tripped); ‘‘caused
by a severe trauma’’ (sporting injury; motor vehicle accident;
heavy object fell or hit the body); ‘‘bone broke with no fall or
injury’’; and ‘‘other’’ when it was marked as the answer. In the
year 3 survey only, two additional response choices were added:
‘‘fainted or lost consciousness’’ and ‘‘my legs gave way’’. These
were included in the category of ‘‘caused by a fall’’.
The calendar season of the fracture was determined by the
month in which it was reported: in all sites except Australia, the
months of December, January and February were considered
winter; March, April and May were considered spring; June, July
and August were considered summer; and September, October
and November were considered fall. In Australia, the seasons were
reversed.
The data were analyzed for all subjects combined, and are also
described for four age subgroups: #64, 65–74, 75–84 and $85
years for the analysis of how fractures occurred. All analyses were
conducted using SAS version 9.2.
Results
Between October 2006 and February 2008, a total of 60,393
postmenopausal women were enrolled across the 10 participant
countries, including those from practices in the United States of
America (28,170), France (5080), the United Kingdom (4079),
Canada (3985), Belgium (3692), Germany (3465), Italy (3252),
Australia (2904), Spain (2910) and the Netherlands (2856). Of the
60,393 women enrolled, 51,491 completed the year 1 question-
naire, 48,750 completed the year 2 questionnaire and 45,490
completed the year 3 questionnaire; there were 42,216 women
with continuous follow-up for all survey years for a crude total
response rate of 70%.
A total of 4268 first incident fractures were reported during the
first 3 years of follow-up. Women who reported multiple fractures
(n = 146) were excluded from the analysis, leaving a total of 4122
first incident single fractures. Basic demographics for all groups are
shown in Table 1. The majority were NHNV fractures (n = 3542,
86%), followed by vertebral (n = 349, 8%) and hip (n = 231, 6%)
fractures.
When Fractures Occurred
As shown in Figure 1, fractures in the GLOW population
occurred across the seasons of the year. For spine and NHNV
fractures, the small seasonal variability was not significant.
However, there was significant variation in the rate of hip
fractures across the seasons (P=0.01), with a significantly higher
hip fracture rate in the spring (32% occurred then) compared with
the other seasons. Looking at the United States of America only,
the seasonal pattern of hip fractures was similar, but was only
borderline significant (P=0.05).
Where Fractures Occurred
Figure 2 illustrates the location of the fracture event by fracture
type. Fractures were described as occurring inside or outside the
home. For hip fractures, there was a fairly even division between
inside and outside (52% vs 48%, P=0.45). Significantly more
vertebral fractures occurred inside the home than outside (61% vs
39%, P,0.001), while NHNV fractures occurred more commonly
outside than in the home (65% vs 35%, P,0.001).
How Fractures Occurred
The events leading to a fracture are shown in Figure 3,
depicting the percentages of women reporting the various causes
of fracture by each of the three fracture types. Overall, the most
common proximate cause for any fracture type was slipping or
tripping (more than half of hip and NHNV fractures and almost
30% of spine fractures). The proportions of spine fractures due to
slipping/tripping or from a fall on the stairs were significantly
lower than for the other two types of fracture (P,0.05). A
relatively small proportion of women experienced fractures related
to sporting injuries, but this category accounted for a significantly
higher proportion of NHNV fractures compared to the other two
fracture types (P,0.05). Fractures with no fall or injury and
‘‘other’’ reasons accounted for a significantly greater proportion of
spine fractures than of the other two fracture types (P,0.05).
Circumstances associated with fractures by age group are shown
in Figure 4. Of note, a fall as the proximate cause of hip fracture
rose from about two thirds of cases in women aged #64 years and
trended upward (P=0.13) with advancing age to being the cause
of more than 80% of hip fractures in the most elderly group
When, Where and How Osteoporotic Fractures Occur
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(Figure 4A). This trend was likely not significant due to the small
number of hip fractures leading to a lack of power to show a
significant relationship. Conversely, trauma as the cause of hip
fracture, which accounted for about 10% in women aged 65–74
years, decreased to approximately 2% in women aged $75 years.
A small minority of hip fractures occurred with no fall or injury in
all age groups, and as age increased the absence of a fall or injury
at the time of hip fracture became even less common. For spine
fractures, about 45% were associated with a fall and about 20%
Table 1. Baseline characteristics, overall and by fracture type (n = 4,122).
Any Fracture
(n =4,122) Type of Fracture Excluded (n =146)
Hip (n=231) Spine (n =349) NHNV (n=3,542)
Age 69 (62–77) 77 (71–83) 72 (66–79) 68 (62–76) 74 (65–82)
Body mass index 26 (23–29) 25 (22–28) 25 (23–29) 26 (23–29) 26 (22–29)
Region
Canada/Australia 502 (12) 17 (7.4) 36 (10) 449 (13) 25 (17)
Europe 1,645 (40) 90 (39) 126 (36) 1,429 (40) 57 (39)
USA 1,975 (48) 124 (54) 187 (54) 1,664 (47) 64 (44)
Number of co-occurring conditions*
0 1,386 (34) 59 (26) 99 (28) 1,228 (35) 30 (21)
1 1,704 (41) 106 (46) 139 (40) 1,459 (41) 57 (39)
$2 1,032 (25) 66 (29) 111 (32) 855 (24) 59 (40)
Number of falls in past 12 months
0 2,104 (52) 113 (50) 177 (51) 1,814 (52) 61 (42)
1 1,039 (26) 55 (25) 95 (27) 889 (25) 38 (26)
$2 923 (23) 56 (25) 75 (22) 792 (23) 46 (32)
Prior fracture at baseline 1,527 (38) 87 (39) 158 (46) 1,282 (37) 86 (60)
Weight ,125 lb (,57 kg) 721 (18) 54 (24) 62 (18) 605 (17) 30 (21)
Parental history of hip fracture 760 (21) 47 (23) 70 (23) 643 (21) 29 (25)
Current smoker 374 (9.2) 13 (5.7) 40 (12) 321 (9.2) 12 (8.4)
Current glucocorticoid 194 (4.8) 13 (5.7) 26 (7.6) 155 (4.5) 14 (9.9)
Alcohol misuse (.20 drinks/week) 28 (0.7) 2 (0.9) 0 (0.0) 26 (0.7) 1 (0.7)
Data given as median (interquartile range) or count (%).
*Asthma, chronic bronchitis or emphysema, osteoarthritis or degenerative joint disease, rheumatoid arthritis, stroke, ulcerative colitis or Crohn’s disease, celiac disease,
Parkinson’s disease, multiple sclerosis, cancer, type 1 diabetes.
NHNV, non-hip–non-vertebral.
doi:10.1371/journal.pone.0083306.t001
Figure 1. Seasonal variation of fracture rates according to
fracture site. Significant differences for each season within fracture
types (P,0.05) are denoted by an asterisk. NHNV, non-hip, non-
vertebral.
doi:10.1371/journal.pone.0083306.g001
Figure 2. Location of occurrence of fracture by fracture type.
Significant differences for each location within fracture types (P,0.05)
are denoted by an asterisk. NHNV, non-hip, non-vertebral.
doi:10.1371/journal.pone.0083306.g002
When, Where and How Osteoporotic Fractures Occur
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e83306
were associated with no fall or injury in all age groups except those
aged $85 years, for whom these findings were reversed, with falls
accounting for 24% and no fall or injury for over 40% in this
oldest group (Figure 4B). For NHNV fractures, there was a
significant upward trend (P,0.0001) for a fall as the proximate
cause with increasing age (and a consistent significant downward
trend (P,0.0001) for trauma for each older age grouping )
(Figure 4C).
Discussion
To determine when, where and how hip, spine and NHNV
fractures occur in postmenopausal women, we analyzed data from
the first 3 years of GLOW. In this large, international, population-
based study of women aged 55 years and older, there were 4122
self-reported first incident fractures, of which most (86%) were
NHNV fractures. Hip fractures occurred nearly equally inside and
outside the home, while most spine fractures occurred inside the
home and most NHNV outside the home. Falls were the dominant
cause for hip and NHNV fractures, and the proportion of these
fractures with a fall as the proximate cause increased with
increasing age.
The effect of seasonality on fractures, especially hip fractures,
has previously been reported from large series in Scandinavia, the
United States of America and Canada. Recent studies from
different areas of Norway have found that hip fracture rates are
highest during the winter [7], particularly for those fractures
occurring outdoors [8], while two older studies did not see a
seasonal variation of effects of cold temperature on the incidence
of hip fractures in Oslo, Norway [9] or Malmo, Sweden [10]. Two
Medicare-based population studies conducted in the United States
of America in the 1980s found that hip fracture rates [11] and
fracture rates for hip, distal forearm, proximal humerus and ankle
fractures [12] were highest in the winter and lowest in the summer.
A study from Canada with data from 1982–1992 found hip
fractures in women aged 60–74 years peaked in mid-December
[13]. The prospective data from GLOW show similar proportions
of NHNV fractures throughout the four seasons, and a signifi-
cantly higher number of hip fractures during spring compared
with the other three seasons. It is possible that lower levels of
vitamin D resulting from a reduction in sunlight exposure over the
winter and clinically manifest in spring might be a contributing
factor to the occurrence of hip fracture in GLOW subjects, but
there were no collections of 25-hydroxy vitamin D data in GLOW
to support or refute this possibility. It is not clear why these data
differ from those in previous studies, but our results may reflect the
broad geographical distribution of the GLOW countries with a
variety of climates, or may represent secular changes in the timing
of fractures since the mid-to-late 1980s, when data for many of the
previous studies were collected.
In GLOW, almost twice as many NHNV fractures occurred
outside the home as inside the home, a finding consistent with
previous studies that have noted that the majority of NHNV
fractures occur outdoors [14,15]. However, we found almost no
difference in the number of hip fracture events occurring inside or
outside the home, in contrast with earlier reports that indicate that
most hip fractures originate at home or in hospices, particularly if
caused by a fall [14-17]. The GLOW population consists of
ambulatory women who may be more health aware and active
than those in earlier studies, particularly as they were recruited
from the practices of the primary care physicians whom they
routinely visited and had volunteered to be a part of this study.
Figure 4. Cause of fractures by age group. A, For hip fractures. B,
For spine fractures. C, For NHNV fractures. NHNV, non-hip, non-
vertebral.
doi:10.1371/journal.pone.0083306.g004
Figure 3. Cause of fracture by fracture type. Significant
differences for each cause between fracture types (P,0.05) are denoted
by an asterisk. Dagger denotes response only available on year 3 survey.
NHNV, non-hip, non-vertebral.
doi:10.1371/journal.pone.0083306.g003
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This study confirms the importance of falling as the principal
proximate cause for the majority of hip and NHNV fractures,
increasing in frequency as a cause of fracture with advancing age.
Though almost half of vertebral fractures in postmenopausal
women aged under 85 years were also preceded by some type of
fall, in the most elderly (.85 years), vertebral fractures were most
often reported in the absence of any fall or injury. While fall
prevention strategies have not been proven to lower fracture rates,
it may still be desirable for patients at risk for fractures to be
provided with advice on how to lower the risk of falls, and efforts
to reduce falls both in the home and outside the home should be
applied throughout all seasons of the year, not solely in the winter.
A major strength of this study is the use of a standard
questionnaire for all countries, minimizing methodology bias by
collecting data in a uniform manner. Owing to the very large
sample with a broad age range, GLOW provides us with
information representative of women at risk of osteoporosis-
related fractures, including women younger than 65 years, as well
as those who are over 85 years of age.
This study has several important limitations. Fracture informa-
tion was self-reported. Previous studies have shown that self-report
is a reliable and accurate method to obtain information of previous
major fractures, with a greater ascertainment for hip and distal
forearm fractures, but less accurate for clinical vertebral fractures
[18-20]. Vertebral fractures are often asymptomatic, or at least
more likely to be clinically unrecognized, which may account for
the lower accuracy of self-report information, and the underesti-
mation of their incidence [21,22]. In GLOW, we assumed most
vertebral fractures reported by the women were clinical, but it is
possible that some were morphometric fractures noted on a
radiograph taken for some other reason following which women
were told there was evidence of a fracture not previously
recognized clinically. Women with multiple fractures were
excluded from the analysis, and those women tended to be older
and in worse health. However, given the relatively small number
of excluded women their removal is unlikely to significantly alter
the findings of this paper. Finally, vital status was not collected so
death rates and adjusted survey response rates cannot be
calculated.
Conclusions
GLOW is the first multi-national study to provide a broad and
detailed overview of when, where and how contemporary
postmenopausal women experience fractures in several regions
of the United States of America, in parts of several countries in
both northern and southern Europe, in eastern Canada and in
southern Australia. The information provided in this report
underscores the importance of teaching older women who may be
at risk for fracture about falling as an important event that leads to
fracture as well as to emphasize that fractures occur in all seasons
of the year as well as within and outside the home. Such
information should offer clinicians the opportunity to enhance
patient awareness about these aspects of fracture risk that may be
helpful to them.
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